Vendor comparison · 2026
5-Amino-1MQ vendors: 19 compared on COAs and price
MetabolicAlso known as 5-Amino-1-methylquinolinium
Evidence tier
Limited published literature
8 publications over 8 years · trials not yet curated
- Vendors carrying it
- 19
- 18 with a listed price
- Vendors with checkable COAs
- 10
- 10 publish any certificate
- Lots tested
- 19
- 19 naming a checkable lab
- Independent assays
- 0
- none on file yet
- Newest assay
- 6 Sept 2026
- oldest 17 Aug 2025
- Laboratories named
- 6
- most often Freedom Diagnostics Testing
- Median label gap
- 7.4%
- 37% of lots within 5% of label
- Median purity
- 99.80%
- 18 of 19 lots at 99% or above
- Lowest price per mg
- $0.800
- peer median $3.30
- Publications located
- 8
- researched since 2018
Source: PepIndex, an independent index of research-peptide vendors. No vendor can pay for a rank, every score is computed by a published formula, and every figure links to the document it was read from.
PeptidePlugs has the most checkable 5-Amino-1MQ testing in this index: 5 lots assayed by Freedom Diagnostics Testing, the newest on 30 Aug 2026. The lowest listed price is $0.800 per mg at Next Gen Peptides, against a peer median of $3.30. 19 vendors carrying 5-Amino-1MQ are compared below. 10 publish at least one certificate naming a checkable laboratory, 19 lot records are on file, and none is an independently commissioned assay. Figures are PepIndex's own: it is an independent index of research-peptide vendors, no vendor can pay for a rank, and each figure links to the certificate it was read from.
Every vendor carrying 5-Amino-1MQ
| # | Vendor | Score here | Price / mg | Lots | Newest test | Laboratory | Mean purity | Label gap | Reports |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Origin LabsISO/IEC 17025 | 96.9100% | — | 1 / 1 | Freedom Diagnostics Testing | 99.9% | 16.3% | ||
| 2 | Next Gen PeptidesISO/IEC 17025 | 93.697% | $0.800 (30%) | 2 / 2 | ILS Laboratories | 99.7% | 5.4% | ||
| 3 | Ascend ScienceISO/IEC 17025 | 93.494% | $0.900 (30%) | 1 / 1 | Kovera Labs and/or ILS Labs | 99.6% | 2.0% | ||
| 4 | Amino ClubISO/IEC 17025Age-gated COAs | 92.598% | $1.00 (30%) | 0 | — | — | — | — | |
| 5 | PeptidePlugs | 91.394% | $1.80 (55%) | 5 / 5 | Freedom Diagnostics Testing | 99.8% | 7.4% | ||
| 6 | Modern AminosISO/IEC 17025COAs need an account | 87.997% | $1.98 (60%) | 4 / 4 | Freedom Diagnostics Testing, Vanguard Laboratory | 99.5% | 8.7% | ||
| 7 | Protide HealthAge-gated COAs | 84.892% | $2.20 (67%) | 1 / 1 | Freedom Diagnostics Testing | 99.7% | 12.1% | ||
| 8 | One Aminos | 83.689% | $3.00 (91%) | 1 / 1 | United Laboratories | 99.9% | 4.8% | ||
| 9 | Licensed Peptides | 80.687% | $1.80 (55%) | 1 / 1 | Vanguard Laboratory | 99.8% | 7.8% | ||
| 10 | Northline LabsISO/IEC 17025 | 77.395% | $4.00 (121%) | 1 / 1 | ILS Laboratories | 100.0% | 7.4% | ||
| 11 | Improved Peptides | 74.187% | $1.50 (46%) | 0 | — | — | — | — | no reportVisit site |
| 12 | Ascension Peptides | 69.989% | $5.20 (158%) | 2 / 2 | MZ Biolabs | 99.0% | 14.7% | ||
| 13 | NeuroLabs Research | 67.891% | $7.19 (218%) | 0 | — | — | — | — | no reportVisit site |
| 14 | Bench Grade Peptides | 67.789% | $8.00 (242%) | 0 | — | — | — | — | no reportVisit site |
| 15 | Eternal Peptides | 60.263% | $3.60 (109%) | 0 | — | — | — | — | no reportVisit site |
| 16 | BioLongevity Labs | 57.272% | $5.00 (152%) | 0 | — | — | — | — | no reportVisit site |
| 17 | Good Science Bio | 54.571% | $6.50 (197%) | 0 | — | — | — | — | no reportVisit site |
| 18 | True Research Labs | 5168% | $5.90 (179%) | 0 | — | — | — | — | no reportVisit site |
| 19 | Mile High Compounds | 47.591% | $11.00 (250%) | 0 | — | — | — | — | no reportVisit site |
Independent assays
No independently commissioned assay of 5-Amino-1MQ is on file. All 19 records below were published by the vendor that sells the product, naming the laboratory shown. PepIndex does not yet commission its own assays, so nothing on this page establishes what is in a vial beyond the vendor’s own certificate. A record moves into this section the moment an assay commissioned by anyone other than the seller is indexed.
What the certificates show
18 of 19 lots at 99% or above; median 99.80%.
| Range | lots |
|---|---|
| <95% | 0 |
| 95–97% | 0 |
| 97–98% | 0 |
| 98–99% | 1 |
| 99–99.5% | 3 |
| ≥99.5% | 15 |
37% of lots within 5% of the labelled mass; median gap 7.4%.
| Range | lots |
|---|---|
| ≤2% | 3 |
| 2–5% | 4 |
| 5–10% | 6 |
| 10–20% | 5 |
| >20% | 1 |
18 vendors, $0.800 to $11.00; median $3.30.
| Range | vendors |
|---|---|
| $0–$5.00 | 11 |
| $5.00–$10.00 | 6 |
| $10.00–$15.00 | 1 |
Purity and mass are read from each certificate as published; the label gap is |labeled − assayed| ÷ labeled. Every value behind these bars is in the certificate table below.
Laboratories used
| Laboratory | Lots | Vendors | Share | Verify |
|---|---|---|---|---|
| Freedom Diagnostics TestingUS | 10 | 4 | 53% | Public lookup |
| ILS LaboratoriesUS | 3 | 2 | 16% | Public lookup |
| MZ BiolabsUS | 2 | 1 | 11% | No public lookup found |
| Vanguard LaboratoryUS | 2 | 2 | 11% | No public lookup found |
| Kovera Labs and/or ILS Labs | 1 | 1 | 5% | No public lookup found |
| United LaboratoriesIN | 1 | 1 | 5% | Public lookup |
Every certificate record
Score breakdown
The score has two halves: the research base — how long the compound has been studied and how much has been published — and the quality of the evidence the market produces for it, aggregated across every vendor that carries it: assayed purity, lot-to-lot consistency, readable third-party certificates and those vendors’ review record. It measures the evidence base, not the merits or safety of the substance.
Studied since 2018 — 8 years of published research
How long the compound has been studied. Fifteen years or more of published literature earns full marks; a newer compound earns less.
8 publications indexed in PubMed
The volume of published literature located. Full marks at fifty or more publications.
Mean assayed purity 99.6% across 19 certificates
Average assayed purity on the certificates published by vendors that carry this compound. Full marks at 99.5%+, nothing at 95% or below.
±0.38 pts purity across lots, mean label deviation 8.6%
How tightly assayed purity and labeled-versus-actual mass hold across different lots. Rewards reproducible manufacturing.
19 of 19 listing vendors publish an accessible certificate policy
Whether the vendors carrying this compound publish per-lot certificates anyone can read without an account.
19 of 19 certificates from a recognised independent lab
Share of certificates issued by a recognised third-party testing lab rather than an unnamed or self-named one.
What is 5-Amino-1MQ?
A small-molecule inhibitor of the enzyme nicotinamide N-methyltransferase (NNMT), studied in the context of metabolism and adipose tissue. It is supplied as a research chemical rather than a peptide.
Studied in published research for metabolic health and fat loss, as an inhibitor of the NNMT enzyme.
Regulatory status
Labeled by vendors for laboratory research use only. Not approved as a medicine in the United States, United Kingdom, or European Union.
What the research examines
The areas of published research this compound appears in. These describe what the literature has studied — never a claim of benefit, effect or suitability for any use.
Published research
Published work is preclinical, in cell and animal models of metabolism and obesity. PepIndex does not evaluate clinical significance and does not describe administration.
- NAD(+) metabolism enzyme NNMT in cancer-associated fibroblasts drives tumor progression and resistance to immunotherapy by modulating macrophages in urothelial bladder cancer — Journal for immunotherapy of cancer (2024)
Peer-reviewed article indexed in PubMed, published in Journal for immunotherapy of cancer (2024).
- Adipose tissue as a source of nicotinamide N-methyltransferase and homocysteine — Atherosclerosis (2009)
Peer-reviewed article indexed in PubMed, published in Atherosclerosis (2009).
- Reduced calorie diet combined with NNMT inhibition establishes a distinct microbiome in DIO mice — Scientific reports (2022)
Peer-reviewed article indexed in PubMed, published in Scientific reports (2022).
- Small molecule inhibitor of nicotinamide N-methyltransferase shows anti-proliferative activity in HeLa cells — Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology (2021)
Peer-reviewed article indexed in PubMed, published in Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology (2021).
- Glucose availability regulates nicotinamide N-methyltransferase expression in adipocytes — Life sciences (2020)
Peer-reviewed article indexed in PubMed, published in Life sciences (2020).
- Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice — Biochemical pharmacology (2018)
Peer-reviewed article indexed in PubMed, published in Biochemical pharmacology (2018).
PepIndex describes what literature exists. We do not interpret it, assess clinical significance, or publish quantities, protocols or instructions for use.